Hairmax Partners with Truemed to Accept FSA/HSA Payments on FDA-Cleared Laser Hair Growth Devices

Boca Raton, FL, June 18, 2025 (GLOBE NEWSWIRE) — Medical-Grade Hair Growth Devices Now Eligible for Pre-Tax Funds
Hairmax, the global leader in laser hair growth technology, is proud to announce a new partnership with Truemed, enabling customers to use FSA (Flexible Spending Account) and HSA (Health Savings Account) funds to purchase eligible Hairmax hair growth medical devices. This collaboration makes Hairmax's full line of Laser Hair Growth solutions—including Laser Caps, Laser Combs, and Laser Band devices—eligible for payment with pre-tax healthcare dollars. This allows customers to save up to 30% or more instantly compared to traditional out-of-pocket spending.
Hairmax laser devices are classified as FDA-cleared medical devices, clinically proven to treat hereditary hair loss and thinning in both men and women. These medical-grade devices use low-level laser therapy (LLLT), a safe, non-invasive, and drug-free treatment that stimulates hair growth, reverses thinning, and increases density and fullness. Backed by decades of clinical research, Hairmax devices are trusted by physicians and hair restoration experts around the world.
'Our partnership with Truemed aligns with our mission to make medically validated hair growth technology accessible to more people,' said Mike Nassar, President of Hairmax. 'Now, customers can invest in their hair health using pre-tax dollars, making it easier and more affordable to take action against hair loss.'
At Truemed, we're excited to broaden our reach through our partnership with Hairmax, a company that shares our commitment to delivering meaningful, health-focused solutions. This collaboration reflects our mission to make health interventions more accessible by enabling HSA/FSA coverage for eligible products that truly improve lives.' – Chantel Hopper, VP of Customer Success & Marketing at Truemed.
In addition to immediate savings, this partnership offers critical year-end benefits. FSA funds typically follow a 'use-it-or-lose-it' policy and must be spent before December 31st. Consumers looking to maximize the value of their remaining 2025 healthcare benefits now have a unique opportunity to invest in clinically proven hair regrowth before their funds expire.
To take advantage of this opportunity, customers can now select the 'Pay with FSA/HSA' option at checkout on Hairmax.com, where Truemed will seamlessly verify eligibility and process the transaction.
About Hairmax
Hairmax is the pioneer and global leader in laser hair growth technology, with over 24 years of innovation and the most FDA clearances in the industry. Hairmax devices are clinically proven and physician-recommended for the treatment of hereditary hair loss and thinning hair. The brand's comprehensive portfolio includes laser devices, hair care, and supplements designed to restore confidence and support a healthy hair growth journey.
About Truemed
About Us blurb: Over $140 billion in HSA/FSA funds sit untouched, with many account holders unaware that their dollars can be spent on more than just prescriptions, doctor's visits, and traditional 'sick-care.' Truemed helps qualified Americans unlock the full potential of these accounts, enabling them to use pre-tax funds on products that help cure, treat, mitigate, and prevent chronic disease, like fitness equipment, supplements, red light therapy, and more. Truemed's curated marketplace and seamless process make it easier to spend smarter and live healthier. Learn more at www.truemed.com .
Learn more at https://hairmax.com/pages/fsa_hsa
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

an hour ago

• Yahoo

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2 Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical data On track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all patients who have received at least one treatment of [212Pb]VMT-α-NET and anti-tumor activities in patients dosed to date who have had the opportunity to receive at least one scan after their full treatment SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S. Food and Drug Administration (FDA) to open the third dosing cohort (Cohort 3) of its ongoing Phase 1/2a clinical trial for [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT). "We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial," commented Markus Puhlmann, Chief Medical Officer of Perspective. "We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile. Meanwhile, we remain committed to engaging with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of our proprietary RPTs." Patients in Cohort 3 will receive up to four fixed administered doses of [212Pb]VMT-α-NET at 6 mCi every eight weeks if they weigh more than 60kg (133lb), or 100μCi/kg of body weight if they weigh less than or equal to 60kg. Observations of dose limiting toxicities (DLTs) in up to eight patients within 42 days of the first treatment cycle will be used to assess whether this cohort of patients have received maximum tolerated dose (MTD) or maximum feasible dose (MFD). Once a safety monitoring committee (SMC) has reviewed the data from these initial patients, it may recommend exploring alternative dosing and/or recruit more patients into Cohort 3. Perspective is notifying sites that Cohort 3 is now open for recruitment. Patients currently being evaluated for entry into the study will enroll into Cohort 3 if they qualify. Pending feedback from sites on operationalizing enrollment into Cohort 3, an update on pace of recruitment will be provided in due course. About [212Pb]VMT-α-NETPerspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study ( identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol. About Perspective Therapeutics, Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations. For more information, please visit the Company's website at Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's belief that it is on track to submit further clinical updates to scientific congresses in 2H 2025 and the planned content of such updates; the Company's ability to explore a higher dose level of VMT-α-NET; the Company's commitment to engage with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of its proprietary RPTs; the Company's expectation that patients currently being evaluated for entry into its VMT-α-NET study will enroll into Cohort 3 if they qualify; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Media and Investor Relations Contacts: Perspective Therapeutics IR:Annie J. Cheng, CFAir@ Russo Partners, LLCNic JohnsonPerspectiveIR@

Bloomberg

4 hours ago

• Bloomberg

A Vaping Victory for Big Tobacco Masks the Real Issue

On Friday, the US Supreme Court waded into the confusing, on-again, off-again effort by the Food and Drug Administration to regulate e-cigarettes ... and didn't get too far. In voting 7-2 to allow a suit by RJ Reynolds Vapor Company against the agency to continue, the justices ruled on a tricky procedural issue and, I think, got the answer right. The litigation is far from over, but recent scholarly work suggests that the ban itself might be a mistake. To understand the case, it's useful to review a bit of history. In 2000, the Supreme Court struck down the FDA's efforts to regulate most tobacco products. Nevertheless, in 2008, the agency began seizing e-cigarettes imported into the US. The following year, Congress passed the Family Smoking Prevention and Tobacco Control Act, which, among other things, required FDA approval before the marketing of any 'new' tobacco product. The courts swiftly held that the authority covered vaping devices. But rather than disrupt what had by then become a substantial market, the agency allowed companies to continue selling their e-cigarette products while it processed their applications.

Time Business News

5 hours ago

• Time Business News

Should You Hire a Driver After SAP Program Completion? Pros and Cons for 2025

Should you hire a driver after SAP program completion? This is a common question many fleet managers and employers in the trucking industry are asking in 2025. With FMCSA and DOT compliance requirements growing stricter, understanding the benefits and risks of hiring SAP-cleared drivers is essential for making informed staffing decisions. The DOT SAP Program (Substance Abuse Professional Program) is designed to rehabilitate drivers who violated drug and alcohol policies. After successful SAP program completion, these drivers are legally eligible to return to safety-sensitive duties — but does that mean you should immediately put them back on the road? ✔ For complete guidance on DOT SAP compliance, visit our DOT SAP Program page. Drivers who finish the SAP process meet DOT's Return-to-Duty standards, ensuring your company remains legally compliant. Drivers given a second chance may demonstrate improved loyalty and commitment, reducing turnover risks. SAP-cleared drivers are subject to follow-up testing, making them one of the most monitored groups on the road — reducing immediate safety concerns. ✔ Learn more about SAP Evaluation to understand the process drivers undergo. Some insurers may raise premiums if your fleet includes drivers with past DOT violations, impacting operational costs. Despite SAP clearance, employers may still worry about reliability or potential relapse, affecting team trust. Clients or partners may view employing SAP-cleared drivers as a liability, influencing business relationships. Employers have the right to make hiring decisions even after SAP program completion but cannot discriminate solely based on past SAP participation. Decisions must align with EEOC guidelines and internal company policies. ✔ For a detailed compliance guide, check the FMCSA Clearinghouse Rules. Q1: Is it mandatory to rehire a driver after SAP program completion? No, employers are not legally required to rehire SAP-cleared drivers but must document valid, non-discriminatory reasons for refusal. Q2: Does SAP program completion erase a driver's past violation from records? No. The violation remains on file in the FMCSA Clearinghouse for five years or until follow-up testing is complete. Q3: Can a driver apply to other companies after SAP program completion? Yes, drivers are free to seek employment elsewhere, but all prospective employers must review Clearinghouse records. Deciding whether to hire a driver after SAP program completion requires balancing safety, cost, legal compliance, and company culture. While SAP-cleared drivers meet DOT standards, your final decision should align with fleet risk management goals. For trusted DOT SAP Evaluation and employer compliance solutions, visit: 🔗 Or explore SAP services at: 🔗 TIME BUSINESS NEWS